Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2010
Molecular identification of Trypanosoma cruzi discrete typing units in end-stage chronic Chagas heart disease and reactivation after heart transplantationJuan Miguel Burgos, Mirta Diez, Carlos Vigliano, et al.
Clinical Transplantation|June 12, 2024
Veno-arterial ECMO ventricular assistance as a direct bridge to heart transplant: A single center experience in a low-middle income countryLucrecia M Burgos, Fiorella S Chicote, Mariano Vrancic, et al.
Medicina|April 27, 2021
Collaborative registry of pulmonary hypertension in Argentina (RECOPILAR). Final analysisDiego F Echazarreta, Eduardo R Perna, María L Coronel, et al.
American Heart Journal|August 2, 2024
Inferior vena CAVA and lung ultraSound-guided therapy in acute heart failure: A randomized pilot study (CAVAL US-AHF study)Lucrecia María Burgos, Rocio Consuelo Baro Vila, Franco Nicolás Ballari, et al.
Respiratory Medicine and Research|December 23, 2022
Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter studyMirta Diez, Jorge Cáneva, Ana Diez, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
Diabetes Care|December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HFSilvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
Pageof 6